Douglas Reed
Director/Board Member presso Viamet Pharmaceuticals Corp.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Robert J. Schotzinger | M | 63 |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.
Innocrin Pharmaceuticals Holdings LLC
 Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC.
Innocrin Pharmaceuticals, Inc.
 Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | 13 anni |
| S. Torres | M | 61 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC.
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | 15 anni |
| Andrew von Eschenbach | M | 82 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC.
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | 13 anni |
| Fred Eshelman | M | 76 |
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC.
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | - |
| Jonathan Thompson | M | - |
Standard Bariatrics, Inc.
 Standard Bariatrics, Inc. Medical SpecialtiesHealth Technology Standard Bariatrics, Inc. operates as a surgical procedure company focused on the development and commercialization of medical devices. It offers STANDARD CLAMP, a laparoscopic surgical device designed to clamp the entire length of the stomach, enabling surgeons to plan and hold the staple line prior to dividing the stomach during laparoscopic sleeve gastrectomy. The company was founded by Jonathan Thompson in 2014 and is headquartered in Cincinnati, OH. | - |
| Kristopher Wood | M | 52 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | - |
| Matt Sokany | M | - |
Standard Bariatrics, Inc.
Standard Bariatrics, Inc. Medical SpecialtiesHealth Technology Standard Bariatrics, Inc. operates as a surgical procedure company focused on the development and commercialization of medical devices. It offers STANDARD CLAMP, a laparoscopic surgical device designed to clamp the entire length of the stomach, enabling surgeons to plan and hold the staple line prior to dividing the stomach during laparoscopic sleeve gastrectomy. The company was founded by Jonathan Thompson in 2014 and is headquartered in Cincinnati, OH. | - |
| Michael Dudley | M | - |
Qpex Biopharma, Inc.
 Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Qpex Biopharma, Inc. develops a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. The company is headquartered in San Diego, CA. | - |
| Ravish Sachar | M | - |
Contego Medical, Inc.
 Contego Medical, Inc. Medical SpecialtiesHealth Technology Contego Medical LLC develops novel emboli protection devices. Its products include CORGUARD coronary stent system, VANGUARD renal stent system, and PALADIN carotid post-dilation balloon. The company was founded by Ravish Sachar and Jay S. Yadav in 2005 and is headquartered in Raleigh, NC. | 19 anni |
| Jeffrey Edwards | M | 64 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| Adrian Howd | M | 52 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| Garheng Kong | M | 49 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.
Southeast BIO
| 6 anni |
| Mike Dial | M | - |
Hatteras Venture Partners
 Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | 15 anni |
| Patrick C. Hutchison | M | 66 | 10 anni | |
| Clay Thorp | M | 55 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | 24 anni |
| Dick L. Sherman | M | 76 | 12 anni | |
| Jay S. Yadav | M | - |
Contego Medical, Inc.
Contego Medical, Inc. Medical SpecialtiesHealth Technology Contego Medical LLC develops novel emboli protection devices. Its products include CORGUARD coronary stent system, VANGUARD renal stent system, and PALADIN carotid post-dilation balloon. The company was founded by Ravish Sachar and Jay S. Yadav in 2005 and is headquartered in Raleigh, NC. | 19 anni |
| John Crumpler | M | - |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | 24 anni |
| Rick S. Kent | M | 74 |
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC.
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | - |
| David Stern | M | - |
Contego Medical, Inc.
Contego Medical, Inc. Medical SpecialtiesHealth Technology Contego Medical LLC develops novel emboli protection devices. Its products include CORGUARD coronary stent system, VANGUARD renal stent system, and PALADIN carotid post-dilation balloon. The company was founded by Ravish Sachar and Jay S. Yadav in 2005 and is headquartered in Raleigh, NC. | - |
| Theodore J. Theophilos | M | 70 |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| Benjamin Scruggs | M | - |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | 8 anni |
| John Sayward | M | 73 | 16 anni | |
| Adam Dunki-Jacobs | M | - |
Standard Bariatrics, Inc.
Standard Bariatrics, Inc. Medical SpecialtiesHealth Technology Standard Bariatrics, Inc. operates as a surgical procedure company focused on the development and commercialization of medical devices. It offers STANDARD CLAMP, a laparoscopic surgical device designed to clamp the entire length of the stomach, enabling surgeons to plan and hold the staple line prior to dividing the stomach during laparoscopic sleeve gastrectomy. The company was founded by Jonathan Thompson in 2014 and is headquartered in Cincinnati, OH. | 8 anni |
| Daniel Burgess | M | 62 |
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Qpex Biopharma, Inc. develops a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. The company is headquartered in San Diego, CA. | - |
| Philip R. Tracy | M | 81 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | 9 anni |
| Mitch Silver | M | - |
Contego Medical, Inc.
Contego Medical, Inc. Medical SpecialtiesHealth Technology Contego Medical LLC develops novel emboli protection devices. Its products include CORGUARD coronary stent system, VANGUARD renal stent system, and PALADIN carotid post-dilation balloon. The company was founded by Ravish Sachar and Jay S. Yadav in 2005 and is headquartered in Raleigh, NC. | - |
| Kyp Sirinakis | F | - |
Southeast BIO
| 6 anni |
| Joseph DeSimone | M | - |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| Geeta S. Vemuri | M | - |
Southeast BIO
| - |
| Karen Spilizewski | F | - |
Standard Bariatrics, Inc.
Standard Bariatrics, Inc. Medical SpecialtiesHealth Technology Standard Bariatrics, Inc. operates as a surgical procedure company focused on the development and commercialization of medical devices. It offers STANDARD CLAMP, a laparoscopic surgical device designed to clamp the entire length of the stomach, enabling surgeons to plan and hold the staple line prior to dividing the stomach during laparoscopic sleeve gastrectomy. The company was founded by Jonathan Thompson in 2014 and is headquartered in Cincinnati, OH. | 6 anni |
| Stacey Enxing Seng | M | - |
Contego Medical, Inc.
Contego Medical, Inc. Medical SpecialtiesHealth Technology Contego Medical LLC develops novel emboli protection devices. Its products include CORGUARD coronary stent system, VANGUARD renal stent system, and PALADIN carotid post-dilation balloon. The company was founded by Ravish Sachar and Jay S. Yadav in 2005 and is headquartered in Raleigh, NC. | - |
| Kurt Azarbarzin | M | 61 |
Standard Bariatrics, Inc.
Standard Bariatrics, Inc. Medical SpecialtiesHealth Technology Standard Bariatrics, Inc. operates as a surgical procedure company focused on the development and commercialization of medical devices. It offers STANDARD CLAMP, a laparoscopic surgical device designed to clamp the entire length of the stomach, enabling surgeons to plan and hold the staple line prior to dividing the stomach during laparoscopic sleeve gastrectomy. The company was founded by Jonathan Thompson in 2014 and is headquartered in Cincinnati, OH. | 5 anni |
| Myla Lai Goldman | F | - |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| Brian K. Adams | M | - |
Southeast BIO
| - |
| Michal Silverberg | F | 48 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| Kseniya Simpson | M | - |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | 5 anni |
| Gregory Duncan | M | 59 |
Southeast BIO
| - |
| Volker Herrmann | M | - |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 9 anni |
| John Lepore | M | - |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| Nancy Thornberry | F | 67 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| Joyce Erony | F | 64 |
Contego Medical, Inc.
Contego Medical, Inc. Medical SpecialtiesHealth Technology Contego Medical LLC develops novel emboli protection devices. Its products include CORGUARD coronary stent system, VANGUARD renal stent system, and PALADIN carotid post-dilation balloon. The company was founded by Ravish Sachar and Jay S. Yadav in 2005 and is headquartered in Raleigh, NC. | - |
| Charlie Sanders | M | 91 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| Martin Murphy | M | 81 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| Mike Gutch | M | 58 |
Southeast BIO
| - |
| William Hawkins | M | 70 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| William D. Kirkland | M | 60 |
Southeast BIO
| - |
| Robert W. Holthausen | M | 76 |
The Wharton School of the University of Pennsylvania
| 35 anni |
| Arnold Levine | M | 84 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| Herb Boyer | M | 87 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| Christy Shaffer | M | 66 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | 8 anni |
| Myla Lai-Goldman | M | 66 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | 13 anni |
| Russell Medford | M | 69 |
Southeast BIO
| - |
| Kenneth Lee | M | 76 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | 21 anni |
| Dennis Dougherty | M | 76 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| Todd Brady | M | 52 |
Southeast BIO
| - |
| Stacy Seng | F | 60 |
Contego Medical, Inc.
Contego Medical, Inc. Medical SpecialtiesHealth Technology Contego Medical LLC develops novel emboli protection devices. Its products include CORGUARD coronary stent system, VANGUARD renal stent system, and PALADIN carotid post-dilation balloon. The company was founded by Ravish Sachar and Jay S. Yadav in 2005 and is headquartered in Raleigh, NC. | - |
| Karen Zaderej | F | 62 |
Southeast BIO
| - |
| Susan B. Washer | F | 63 |
Southeast BIO
| - |
| Sean Murphy | M | 71 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | 7 anni |
| Jan P. Turek | M | - |
Southeast BIO
| - |
| Casey Tansey | M | 66 |
Standard Bariatrics, Inc.
Standard Bariatrics, Inc. Medical SpecialtiesHealth Technology Standard Bariatrics, Inc. operates as a surgical procedure company focused on the development and commercialization of medical devices. It offers STANDARD CLAMP, a laparoscopic surgical device designed to clamp the entire length of the stomach, enabling surgeons to plan and hold the staple line prior to dividing the stomach during laparoscopic sleeve gastrectomy. The company was founded by Jonathan Thompson in 2014 and is headquartered in Cincinnati, OH. | - |
| Court Turner | M | - |
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Qpex Biopharma, Inc. develops a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. The company is headquartered in San Diego, CA. | - |
| Fred Gage | M | - |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| Marvin Woodall | M | - |
Contego Medical, Inc.
Contego Medical, Inc. Medical SpecialtiesHealth Technology Contego Medical LLC develops novel emboli protection devices. Its products include CORGUARD coronary stent system, VANGUARD renal stent system, and PALADIN carotid post-dilation balloon. The company was founded by Ravish Sachar and Jay S. Yadav in 2005 and is headquartered in Raleigh, NC. | - |
| Joe C. Cook | M | 82 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| Nancy Hutson | M | 74 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
| H. Thorp | M | - |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | 18 anni |
| Steve D. Weinstein | M | - |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | - |
| Richard Flavell | M | - |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Todd P. Clyde | M | 55 | 11 anni | |
| Mack Gill | M | 72 | 13 anni | |
| Matt Molchan | M | 57 | - | |
| Gerhard Burbach | M | 62 | 9 anni | |
| Bill Bryant | M | 66 |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 8 anni |
| Brenda D. Gavin | M | 76 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | 8 anni |
| J. Buchi | M | 69 | 3 anni | |
| Virgil J. Lott | M | 66 | 12 anni | |
| Farid Harianto | M | 68 |
The Wharton School of the University of Pennsylvania
| 3 anni |
| James Rosen | M | 55 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | - |
| Christopher P. Prior | M | 72 | 6 anni | |
| Seong-Il Kim | M | 70 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 6 anni |
| R. Huennekens | M | 59 | 5 anni | |
| Mark Velleca | M | 60 |
Gilead Connecticut, Inc.
 Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA. | 11 anni |
| Matthew Young | M | 54 |
The Wharton School of the University of Pennsylvania
| 5 anni |
| Jim Woody | M | 81 | 9 anni | |
| Adam Blackman | M | - |
The Wharton School of the University of Pennsylvania
| 5 anni |
| Louis A. Toth | M | - |
The Wharton School of the University of Pennsylvania
| 10 anni |
| William Snider | M | 54 |
The Wharton School of the University of Pennsylvania
| 12 anni |
| Muzammil Mansuri | M | 70 |
Gilead Connecticut, Inc.
Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA. | 3 anni |
| Alex Panos | M | - |
The Wharton School of the University of Pennsylvania
| 9 anni |
| George Martin | M | 65 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | - |
| Michael Kishbauch | M | 75 | 2 anni | |
| Glenn Fuhrman | M | 58 |
The Wharton School of the University of Pennsylvania
| 5 anni |
| Thomas Simpson | M | 63 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA.
The Wharton School of the University of Pennsylvania
| 7 anni |
| Michael Steinmetz | M | 75 | 5 anni | |
| Robert Alexander Ingram | M | 81 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | - |
| David A. Spurling | M | 71 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 6 anni |
| Timothy McNamara | M | 67 |
University of Missouri-Kansas City
| 6 anni |
| Jamie Kramer | F | - |
The Wharton School of the University of Pennsylvania
| 12 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Douglas Reed
- Contatti personali
